ArticleFrontiers in neurology2025
A multitask framework based on CA-EfficientNetV2 for the prediction of glioma molecular biomarkers.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioma is the most common primary malignant tumor of the central nervous system. The mutation status of isocitrate dehydrogenase (IDH) and the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter are key biomarkers for glioma diagnosis and prognosis. Accurate, non-invasive prediction of these biomarkers using MRI is of significant clinical value. Materials and methods: We proposed a novel multitask deep learning framework based on Coordinate Attention-EfficientNetV2 (CA-EfficientNetV2) to simultaneously predict IDH mutation and MGMT promoter methylation status based on MRI data. Initially, unlabeled MR images were annotated using K-means clustering to generate pseudolabels, which were subsequently refined using a Vision Transformer (ViT) network to improve labeling accuracy. Then, the Fruit Fly Optimization Algorithm (FOA) was employed to assign optimal weights to the pseudolabeled data. The CA-EfficientNetV2 model, integrated with a coordinate attention mechanism, was constructed. The multitask framework comprised three independent subnetworks: T2-net (based on T2-weighted imaging), T1C-net (based on contrast-enhanced T1-weighted imaging), and TU-net (based on the fusion of T2WI and T1CWI). Results: The proposed framework demonstrated high performance in predicting both IDH mutation and MGMT promoter methylation status. Among the three subnetworks, TU-net achieved the best results, with accuracies of 0.9598 for IDH and 0.9269 for MGMT, and AUCs of 0.9930 and 0.9584, respectively. Comparative analysis showed that our proposed model outperformed other convolutional neural network (CNN) - based approaches. Conclusion: The CA-EfficientNetV2-based multitask framework offers a robust, non-invasive method for preoperative prediction of glioma molecular markers. This approach holds strong potential to support clinical decision-making and personalized treatment planning in glioma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.